JPM26: 2025 a “breakout year” for rare disease biotechs
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent…
-
FDA increases manufacturing flexibility for cell and gene therapies
The US Food and Drug Administration (FDA) has announced increased flexibility for cell and gene therapy (CGT) manufacturers, loosening quality…
-
Patient burden as an operational metric of clinical trial success
Patient burden should join standard operational metrics like cost, timelines, and regulatory compliance to ensure long-term clinical trial success, argues…
-
Collaboration with partners drives successful clinical trials, says Bayer exec
Closer relationships with clinical trial partners are key to ensuring long-term trial success with German pharma giant Bayer, says the…
-
AI to become as foundational as the internet in clinical trials, experts say
Artificial intelligence (AI) is expected to not only supplement clinical trials, but redefine the sector, while the industry braces for…
-
CTSWC25: The future of clinical trial supply hinges on risk management
Regulatory overhaul, international trade tariffs, and the burgeoning disruption imposed by artificial intelligence (AI) are moving the clinical trials industry…
-
Clinical trial supply chains in the US navigate pharma tariffs
Tariffs imposed by President Trump on US pharma imports have left experts charting a new course for the nation’s clinical…
-
Adapting to funding and operational hurdles in today’s clinical trials landscape
Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries,…
-
AI could personalise clinical trial consent, but privacy concerns remain
Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability…